Annexon (ANNX) - Year-over-year earnings per share growth for the last twelve months
Annexon, Inc. develops advanced therapies for neurodegenerative pathologies, leveraging robust scientific potential. The quarterly EPS growth rate reflects profit dynamics, with the current value standing at 31.50. This underscores volatility amid intense competition with industry behemoths. Management is currently focused on securing major partners to fund the final stages of clinical trials.
Summary analytical data breakdowns for annexonbio.com (ANNX)
- share price and consensus valuation forecast:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
Total Debt to Capital Annexon, Inc.|ANNX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Annexon Inc.|ANNX - Company Aggregate Debt|Debts to Book Capitalization Annexon Biosciences|ANNX - Company Long-Term Liabilities|Company Current Liabilities Annexon|Quick Ratio annexonbio.com
- earnings and market multiples details:
ANNX - Net Profit|Expected Profit Annexon, Inc.|ANNX - Price to Earnings Multiple|Future Price to Earnings Annexon|ANNX - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Annexon, Inc.|ANNX - Operating profit before amortization|Earnings per share for the last twelve months Annexon|ANNX - Earnings per share for the last 12 months|Quarterly EPS earnings growth annexonbio.com|ANNX - Earnings per share growth rate in current year|Expected earnings per share growth for next year Annexon, Inc.
- company sales and revenue statistics:
Summary company analysis:Annexon Biosciences Inc. - ANNX
Investors must objectively assess an asset's fundamental stability to protect capital from inflationary losses. This indicator measures the percentage change in quarterly net earnings per share, reflecting the efficiency of value generation. By analyzing quarterly earnings per share dynamics, one can identify hidden liquidity risks during sharp spikes. For Annexon, Inc. (ANNX), this parameter confirms the financial return from the development of unique neuroprotective therapies. A focus on critical nervous system diseases determines the long-term profitability trend of the business.
Main competitors
BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Bioscience Ltd) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Axsome Therapeutics, Inc. AXSM|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals Inc.)|XENE: Year-over-year net earnings per share trend for the last twelve months|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Supernus Pharmaceuticals (SUPN)|CPRX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Therapeutics)|HRMY: Quarterly EPS earnings growth|BHVN (Biohaven Pharmaceutical) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Amylyx|Quarterly EPS earnings growth Trevi Corp|Quarterly EPS earnings growth PRAX|AVXL (anavex.com) - Year-over-year earnings per one share growth for the last 12 months|CeriBell Inc - Year-over-year net earnings per share growth for the last 12 months|PRTA (Prothena Corporation plc) - Year-over-year net earnings per share trend for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|OMER - Quarterly EPS earnings growth|Neurogene (NGNE) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months AC Immune SA (ACIU)|Year-over-year net earnings per share growth for the last 12 months VYGR|Quarterly EPS earnings growth Neumora Therapeutics Inc|Year-over-year earnings per share growth for the last twelve months scilexholding.com (SCLX)|Year-over-year net earnings per share change for the last twelve months Tevogen Bio Inc.|Year-over-year earnings per share growth for the last twelve months Alpha Cognition Inc. ACOG|Quarterly EPS earnings growth Cognition Therapeutics CGTX|IKT: Year-over-year net earnings per share growth for the last 12 months|SAVA (Cassava Sciences) - Year-over-year earnings per share growth for the last 12 months|Assertio Holdings, Inc. (ASRT) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months COYA|Year-over-year earnings per share growth for the last twelve months Vistagen|Year-over-year net earnings per share growth for the last 12 months Ovid Therapeutics (OVID)|Year-over-year earnings per share growth for the last twelve months Acumen Pharmaceuticals Inc. (ABOS)|CRVO - Earnings per share growth in annualized terms for the last twelve months|Alterity Therapeutics Limited - Year-over-year net earnings per share growth for the last 12 months|CLNN: Year-over-year earnings per share growth for the last 12 months|pepgen.com - Quarterly EPS earnings growth|JUNS (Jupiter Neurosciences) - Year-over-year earnings per share growth for the last 12 months|Relmada (RLMD) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Annovis Bio (ANVS)|GRCE (gracetx.com) - Quarterly EPS earnings growth|Firefly Neuroscience Inc (AIFF) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months KLTO (Klotho Neurosciences Inc)|NeuroSense Therapeutics Ltd - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth RVPH (Reviva Pharmaceuticals, Inc.)|Year-over-year earnings per one share growth for the last 12 months MTVA|NeurAxis Inc - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Helius Medical Technologies, Inc. HSDT|PASG: Quarterly EPS earnings growth|Neuphoria (NEUP) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Minerva Neurosciences Inc|Athira Pharma Inc (ATHA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ADXN (Addex Therapeutics)|Quarterly EPS earnings growth Alzamend Neuro Inc. (ALZN)|Cyclerion Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|PTIX (Protagenic Therapeutics) - Year-over-year net earnings per share trend for the last twelve months|Pasithea Therapeutics Corp - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Cortigent CRGT|ATXI (Avenue Therapeutics, Inc) - Year-over-year net earnings per share growth for the last 12 months|Brainstorm Cell Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CARA|Earnings per share growth in annualized terms for the last twelve months chromocell.com CHRO|Year-over-year earnings per share growth for the last twelve months Eliem Therapeutics, Inc. (ELYM)|ITCI (Intra-Cellular Therapies, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth LBPH (Longboard Pharmaceuticals Inc)|Quarterly EPS earnings growth Marinus Pharma MRNS|nkgenbiotech.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharmaceuticals, Inc.|Sage Therapeutics (SAGE) - Year-over-year earnings per share growth for the last twelve months|SNPX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Trevena, Inc|Vigil Neuroscience (VIGL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth WENA|Quarterly EPS earnings growth cerevel.com (CERE)
